Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benfo-Oxythiamine (B-OT) in Healthy Volunteers
NCT07450833Phase 1Completed
- Sponsor
- benfovir
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of benfo-oxythiamine in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by benfovir. Primary endpoints: Treatment-Emergent Adverse Events at Day 14, Serious Adverse Events at Day 14 and 4 more. Started Mar 2022; status: completed.
02
Drugs
benfo-oxythiamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07450833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450833.